Researchers use genetically-engineered virus to fight skin cancer

A team of researchers have used a genetically-engineered version of a virus, which normally causes cold sores, to fight skin cancer.

Experts said that it could be a new breakthrough in treating skin cancer. The genetically-engineered version of the virus ca be injected into tumours and it replicates and releases substances to help fight the cancer and is harmless to normal cells.The new treatment is called T-Vec.

The treatment is not licensed yet but similar treatments for melanoma are already available in the US and Europe. Researchers have said the newtherapy would be an addition to the existing treatments. This therapy will be the first melanoma treatment that uses a virus for treating skin cancer.

The study was funded by pharmaceutical company Amgen and led by the UK's Institute of Cancer Research. The researchers found that a quarter of patients given T-Vec responded to the treatment. Out of those, about 10 per cent saw their tumours disappear completely, while 16% saw their tumours shrink by half.

The trials were published in the Journal of Clinical Oncology.


AustrianTribune Specials

Health experts have said the avian influenza outbreak has not affected the birds in the state of Alaska in the United Sates.

They said that the large scare outbreak has spread across 48 U.S. states and Canada but is yet to reach the state...

Most Popular

Researchers from the University of Cambridge have made...

NASA has achieved one more milestone in space travel....

According to reports, the Space Coast is all set to...

A team of scientists in Canada are aiming to study the...

Automotive News

  • Toyota reports 19.2% jump in global net profit
  • Tesla Motors acquires & renames west Michigan auto supplier

UK News

  • Study shows air pollution claimed 9,500 lives in London
  • Smelliest titan arum plant blooms in Edinburgh
  • UK drink limits are ‘unsafe’, says doctors
  • London noise levels affecting population
  • Mediterranean diet reduces risk of womb cancer, study